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The possibility that women produce new oocytes post-natally as part of the normal physiological function of the ovary is currently under
investigation. Post-natal production of oocyte-like cells has been detected under experimental conditions in the mouse. Although these
cells have many characteristics of oocytes, their potential to mature to fertilization-competence was unproven. Zou et al. (Production of
offspring from a germline stem cell line derived from neonatal ovaries. Nat Cell Biol 2009;11:631–636) made use of a striking cell isolation
and culture strategy to establish cultures of proliferative germ cells from both newborn and adult ovaries. Their cells, referred to as female
germline stem cells (FGSCs), proliferate long-term in culture and accept and maintain expression of a transgenic marker, green fluorescent
protein. When delivered to the ovaries of conditioned mice, transgene-bearing FGSC engrafted, were enclosed within follicles, and when
host females were mated, transgenic offspring were produced. That proliferative female germ cells capable of giving rise to offspring
were detected in adult ovaries poses the question of whether they have a physiological role. Here, we discuss Zou et al.’s data in terms
of our current understanding of mouse ovarian physiology, and how this may relate to human reproductive biology and the treatment of
ovarian dysfunction.
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Introduction
In mammals, the production of mature, fertilization-competent
oocytes occurs in a remarkably diverse manner (Edwards et al.,
1977; Jensen et al., 2006). The question of whether any mammals
produce new eggs during post-natal life has long been a subject of vig-
orous experimentation and debate. Early in the last century, several
authors reported evidence that rats (Arai, 1920), mice (Parkes
et al., 1927) and rabbits (Pansky and Mossman, 1953) all can
produce new oocytes and regenerate lost ovarian tissue [summarized
in a contemporary review by Everett (1945)]. It was further shown
that oogenesis continues unabated during adult life in some species
of prosimian primates (David et al., 1974), with the stages of
meiotic entry clearly visible in histological preparations of their
ovaries. However, a consensus arose in the middle of the last
century that humans and the most well-studied domestic and labora-
tory animals are endowed with their entire complement of oocytes at
birth (Zuckerman, 1951).
The question of ‘neo-oogenesis’ received renewed attention in this
century when it was shown that the mouse ovary has an unexpected
ability to regenerate immature oocytes after their destruction
(Johnson et al., 2004; Lee et al., 2007). It was shown that both
ovary resident (Johnson et al., 2004) and circulating bone marrow-
derived (Johnson et al., 2005a) stem cells can give rise to new imma-
ture oocytes in the ovary. A counter-example was published soon
thereafter showing that no mature, ovulated oocytes derived from
transplanted cells were produced after bone marrow transplantation
(Eggan et al., 2006). Several reviews discuss the historical ebb and
flow in the field (Johnson et al., 2005b; Tilly and Johnson, 2007),
and indeed, the contentiousness (Telfer et al., 2005; Begum et al.,
2008) of these data.
Here, we consider a recent manuscript in Nature Cell Biology that
reports a novel technical and conceptual advance in this area. Kang
Zou and co-authors from the School of Life Sciences, Shanghai Jiao
Tong University, Shanghai, China, reported that proliferative
ovary-resident cells, termed female germline stem cells (FGSCs),
cannot only give rise to immature oocytes but can produce new
mature, fertilizable oocytes that can produce offspring in vivo (Zou
et al., 2009). Their work is a significant challenge to the dogma that
new fertilization-competent oocytes cannot be produced after birth
in mammals. Here, we first consider the group’s methodology, data
and conclusions, placing their work into context with the previous
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literature. Finally, we ask whether these findings are relevant to the
function of the human ovary as we consider its physiology and ways
to support healthy function and fertility.
Isolation and long-term culture
of proliferative female germ cells
from post-natal ovaries
Zou et al. first sought to confirm the presence of putative FGSCs in
young (5-day-old) and adult mouse ovaries. As oocytes are non-
proliferative by definition, any cells that express germ lineage markers
but are still proliferating would be candidate FGSCs. In keeping with
previous studies (Johnson et al., 2004), Zou et al. detected ovarian
cells within the ovarian surface epithelium that were double-positive
for Mouse Vasa Homolog (MVH) and 5’-bromodeoxyuridine (BrDU)
incorporation. Cells were detected 1 hr after BrDU injection of both
5-day-old and adult mice. Further morphological and histological analy-
sis of the cells was performed, and the authors went on to attempt iso-
lation of these cells for culture in vitro. They used an interesting
immunomagnetic cell sorting approach targeting predicted surface
expression of MVH protein.
MVH is a RNA helicase of the DEAD-box family (Linder, 2006).
The Drosophila orthologue, Vasa, acts as a translational regulator of
mRNAs localized in oocytes, and is required for proper axis determi-
nation in offspring as well as establishment of germ cells (Styhler et al.,
1998; Tomancak et al., 1998; Mahowald, 2001; Riechmann and
Ephrussi, 2001). Mutations in the helicase domain of Vasa directly
result in germ line defects and female sterility in the fly (Lasko and
Ashburner, 1990; Styhler et al., 1998). As it is highly expressed in
the germ cells of both male and female mammals, MVH is a
common molecular marker used for their identification. MVH
expression is required for spermatogenesis and thus male fertility
(Tanaka et al., 2000) in the mouse. In the female, MVH is expressed
in the female germline from late primordial germ cell (PGC) migration
through the mature metaphase II oocyte (Toyooka et al., 2000). The
protein is expressed at extremely high levels in the cytoplasm,
allowing for excellent signal-to-noise in labeling and cell-tracking
experiments.
A pivotal part of Zou et al.’s work is the detection of MVH protein
on the external surface of the plasma membrane of rare (50–100 cells
in the ovaries of 6–8 mice) ovarian cells. In Supplementary Data, they
reference the use of the bioinformatics tool TMPRED (http://www.ch
.embnet.org/software/TMPRED_form.html) to analyze the amino
acid sequence of MVH for potential transmembrane/surface
domains. They state that two transmembrane domains were predicted
by the tool. This justified attempts to target MVH as a potential
surface marker in an immunomagnetic cell sorting strategy after enzy-
matic digestion of ovaries; cells that expressed MVH on their surface
were thus separated from cells that lacked surface MVH expression.
The detection of MVH at the surface of germ cells was surprising as
this had not been previously reported for any of the highly conserved
Vasa orthologues, from flies to man. We used multiple protein
sequence analysis tools, including TMPRED, and also found that pre-
dicted transmembrane domains of MVH could be identified (not
shown). However, these predicted transmembrane domains overlap
with two well-characterized functional motifs in the conserved
DEAD-box RNA helicase portion of MVH, MVH motifs II and
V. These motifs are both known to participate in RNA helicase
activity, including ATP, RNA and intra-protein interactions (Linder,
2006; Sengoku et al., 2006). It is difficult to understand how these
catalytic and binding motifs can simultaneously act as plasma-
membrane-spanning domains. More information is needed about the
surface MVH immunogenicity of FGSC and whether other germ- or
stem-cell markers are expressed on the surface of FGSC.
Questions about surface immunogenicity aside, Zou et al. were able
to establish cultures of cells isolated using their technique that had
remarkable long-term passage characteristics. They showed that
freshly isolated and cultured ‘FGSC’ were proliferative, and confirmed
their expression of MVH using immunostaining and the expression of
eight additional germ cell (and stem cell-below) specific genes. FGSC
did not express markers of either meiosis [Scp1-3 (Yuan et al., 2002)],
more general oocyte development [e.g. Dazl (Ruggiu et al., 1997),
Figla (Joshi et al., 2007) or Dpa3/Pgc7/Stella (Bortvin et al., 2004)
or the ZP3 zona pellucida transcript (Lira et al., 1990)]. FGSC isolated
from newborn mice (nFGSC) and adults (aFGSC) grew in clusters and
were able to be cultured on STO feeder cells for more than 15 and 6
months, respectively.
The long-term growth in culture supported experiments that
assessed the stem cell properties, or, ‘stemness’ of FGSCs. nFGSC
were found to express Oct4 (Scholer et al., 1990; Brehm et al.,
1998) and Nanog (Chambers et al., 2003), and to have high telomer-
ase activity, all characteristics of stem cells.
Importantly, nFGSC were also shown to have a normal karyotype
after extended passages. This combination of the expression of ‘stem-
ness’ related factors (along with the detected germ cell gene
expression) and genomic stability suggested to the authors that
these cells might be coaxed to support oogenesis.
The production of offspring from
ovary-derived FGSCs
Zou et al. addressed the question of whether oocytes could be pro-
duced using FGSC with a direct in vivo approach. In order to track
their cells, they indelibly labelled nFGSC and aFGSC using a retroviral
vector bearing green fluorescent protein (GFP). The treatment of mice
with the chemotherapeutic agents busulfan and cyclophosphamide
depletes ovaries of oocytes (Shiromizu et al., 1984; Johnson et al.,
2004). Animals conditioned in this manner have been used as cell reci-
pients in attempts to produce oocytes, with varying results (Eggan
et al., 2006; Lee et al., 2007).
Published reports have only shown the production of low numbers
of donor-derived immature oocytes (0.1% of all oocytes in recipi-
ents) when bone marrow- or peripheral blood-derived stem cell frac-
tions were delivered to the bloodstream (Lee et al., 2007). Instead,
Zou et al. delivered their cells directly into the ovaries of recipient
animals using pulled glass pipettes. Very strikingly, follicles of all
sizes, including large pre-ovulatory follicles, containing GFP-positive
oocytes were seen in whole mounts and histological preparations
2 months after delivery of nFGSC or aFGSC (Fig. 1A). In fact, nearly
all oocytes shown in fluorescence photomicrographs are unambigu-
ously GFP-positive. The authors reported that oocytes [and] follicles
were not seen in control conditioned animals that did not receive
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FGSC. A quantitative analysis counting GFP-positive oocytes in cell-
delivered versus control animals was not provided. Even so, this unam-
biguous qualitative demonstration that their cell lines were capable of
oogenesis in vivo led to mating trials to see if these labelled oocytes
were capable of supporting fertilization and offspring production.
Mating trials using chemotherapy-conditioned animals that received
ovarian injections of GFP-expressing nFGSC (passaged 45 times) or
aFGSC (in culture for 15 weeks) were similarly successful. Approxi-
mately 80% of animals receiving cell injections produced offspring
after mating with a wild-type male (Fig. 1B). Twenty-nine of 108 off-
spring bore the GFP transgene when nFGSC were used, and 24 of
85 when aFGSC were used.
One might predict that most, if not all offspring produced within
these experiments should be derived from GFP-positive FGSC. Two
factors make this unlikely. First, the busulfan/cyclophosphamide
regimen has been shown to deplete oocytes in a pronounced but
gradual fashion over a period of weeks. This allows for several
litters to be produced from ‘host’ oocytes (Lee et al., 2007) before
their complete eradication. Due to this, the contribution of non-
transgenic host oocytes to offspring could be significant. Second, the
authors strategy for the establishment of labelled GFP-positive FGSC
using retrovirus infection would result in a heterogeneous population
of cells available for transplantation. As the authors make no mention
of establishing clonal FGSC lines, transplanted cells would be expected
to have differing transgene insertion sites and copy numbers. Some
fraction of this population would be expected to lose the transgene
to either the first or second polar body; in this way, an oocyte
derived from a transgenic FGSC could give rise to a wild-type offspring.
It is possible that clonal lines of GFP–FGSC with fully characterized
transgene insertion site(s) will lead to predictable and increased
numbers of transgenic offspring versus the heterogenous population
used here. For these reasons, it is possible that the ability of FGSCs
to generate offspring is underestimated rather than overestimated.
The origins of FGSCs
Zou et al.’s work sets a new standard in the field of oogenesis, where
offspring can indeed be produced from oocytes made anew during
adult life. The stem cells isolated during these studies have remarkable
features, not the least of which is their apparent unipotency, their
demonstrated ability to give rise to one type of cell, the oocyte.
Important questions remain about the origins of FGSCs and their
physiological function in vivo. It is reasonable to ask ‘where do
FGSCs come from?’ and ‘what exactly do these cells do?’.
If one supposes that FGSCs arise during the specification of PGCs,
there are only a few logical explanations for their origins. All of those
germ cells that progress through oogonial proliferation, to germline
cyst formation and breakdown (Pepling and Spradling, 1998, 2001),
and that form primordial follicles are almost certainly disqualified
due to their development into (non-proliferative) oocytes. Are
FGSCs holdover PGCs, or, are they oogonia that somehow avoid
commitment to cyst and follicle formation and arrest in prophase of
meiosis I?
Zou et al. include some data that sheds some light on these ques-
tions. If FGSCs are holdover PGCs, it is reasonable to hypothesize
that these cells should behave as embryonic germ cell (EGC) lines
[see (Kerr et al., 2006) for a review] that can be established from
PGCs. Indeed, FGSCs were shown to have similar long-term prolifer-
ation potential and gene expression profiles as EGCs. However, the
authors show that FGSCs were incapable of development into terato-
mas when injected into the subcutis of nude mice. This contrast with
EGCs that readily develop into teratomas is telling. A recent report
demonstrated that ‘postmigratory’ PGCs, isolated from ovaries as
late as embryonic day 13.5 could be established as EGC lines (Shim
et al., 2008). It is not clear how those authors distinguished between
postmigratory PGCs and oogonia, but their results suggest that the
proliferative germ cells that can be isolated from fetal ovaries at day
13.5 are either distinct from those isolated by Zou et al. in post-natal
ovaries, or included them as an unrecognized cell fraction. A timeline
and schematic is shown in Fig. 2 to illustrate this point; from this infor-
mation, we predict that FGSC arises between the border of PGC and
oogonia development and the initiation of germline cysts.
We must return to the overarching question: is the production of
oocytes by stem cells in mice a normal, physiological process, or,
are these cells only relevant to experimental and treatment modalities?
Accordingly, if the ovaries of mice contain a number of these cells
during adult life, what is their proportional contribution, if any, to
the oocyte pool that exists in the ovary at any time? Are FGSCs
required to support oocyte numbers in the ovary or are they only
stimulated during a crisis? If they can be stimulated to produce new
oocytes, why do ovaries cease to function as in the menopause,
versus the testis where germ stem cells support sperm production
for life? It will take years of clever experimentation to better under-
stand ovarian physiology and what the ovary is truly ‘capable of’ in
terms of its supply of healthy oocytes.
Figure 1 Production of oocytes and offspring after transplantation
of labelled FGSC.
(A) Zou et al. demonstrated that the transplantation of FGSC that expressed
GFP into chemotherapy-treated animals led to the formation of follicles con-
taining GFP-positive oocytes (bottom, compare with wild-type control in top
panel). (B) Animals that received transplants were mated with wild-type
males resulting in litters of offspring, approximately one-quarter of which
were transgenic for GFP (genotyping shown in bottom panel, lanes 1–4 are
transgenic offspring, lanes 5 and 6 are wild-type and lane 7 is a positive
control). Images reproduced with permission of the Nature Publishing Group.
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Do FGSCs exist in the human?
The question of whether such cells exist in female humans must now
be definitively addressed. This work attracts attention from biologists
and the lay public alike, due to hopes that one day healthy babies
will result from such technologies. The function of the ovary is of
course not limited to offspring production, supporting a myriad of
health and wellness parameters in premenopausal women (Perez
et al., 2007; Pal et al., 2008). Thus restored ovarian function using
a woman’s own FGSC equivalent cells would lead to quality of life
improvements in a potentially enormous population of aging
women who might seek out such treatment. As mentioned at the
outset, ovarian physiology between mammalian species is quite
diverse and the strategies used to produce fertilization-competent
oocytes can differ greatly. Indeed, mice are not human. However,
the conservation of molecular mechanisms that guide germline devel-
opment, and produce healthy oocytes between the mouse and
human is undeniable. The tools that Zou et al. used to isolate
FGSCs from newborn and adult mice, when validated, should be
directly applicable to attempts to isolate similar cells from human
ovarian biopsies. Even if germ stem cells do not exist in humans
we will still learn much by investigating the question as we
improve in vitro culture techniques and cell and reagent delivery to
human ovarian tissue. If germ stem cells are found to exist during
adult life in humans, their potential to be stimulated or used in
transplantation regimes to make new oocytes and support ovarian
function and fertility is enormous.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.org/.
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